文献速递神经肿瘤

免疫治疗驱动胶质母细胞瘤患者间充质肿瘤细胞状态转变和肿瘤微环境免疫反应

Immunotherapy drives mesenchymal tumor cell state shift and TME immune response in glioblastoma patients.
PubMed 文献 · Neuro Oncol · 2024-01-01

该研究在单细胞分辨率下分析纳武利尤单抗免疫检查点治疗期间胶质母细胞瘤患者的表型和转录动态,对76例肿瘤样本进行配对单细胞RNA测序分析,发现治疗与向间充质干细胞样肿瘤细胞转变增加及肿瘤相关巨噬细胞、耗竭和增殖T细胞增加相关;在外部数据集(n=298)中验证并开发潜伏免疫特征,发现18%的原发性胶质母细胞瘤样本为潜伏免疫型,与间充质肿瘤细胞状态和肿瘤微环境免疫反应相关,且潜伏免疫型患者在接受免疫检查点治疗后总生存期较短(P=0.0041)。

要点

  • 纳武利尤单抗治疗与胶质母细胞瘤向间充质干细胞样肿瘤细胞转变增加相关。
  • 治疗还伴随肿瘤相关巨噬细胞及耗竭和增殖T细胞增加。
  • 18%的原发性胶质母细胞瘤样本为潜伏免疫型,与间充质肿瘤细胞状态和肿瘤微环境免疫反应相关。

核心结论

  • 在五分之一的胶质母细胞瘤患者中发现一种耐药机制特征,与肿瘤细胞向更具侵袭性的间充质样状态转变、肿瘤相关巨噬细胞及增殖和耗竭T细胞增加相关,这些患者可能反而受益于靶向间充质肿瘤细胞的神经肿瘤治疗。

研究设计与样本

  • 对来自PD-1抑制剂纳武利尤单抗临床试验的患者及未经治疗患者的76例肿瘤样本进行配对的单细胞RNA测序整合分析,并在大型外部胶质母细胞瘤数据集(n=298)中验证和扩展发现。

主要发现

  • 在肿瘤细胞和肿瘤微环境中鉴定出响应纳武利尤单抗的独特侵袭性表型特征。
  • 纳武利尤单抗治疗与向间充质干细胞样肿瘤细胞转变增加相关,并伴随肿瘤相关巨噬细胞及耗竭和增殖T细胞增加。
  • 开发潜伏免疫特征,发现18%的原发性胶质母细胞瘤样本为潜伏免疫型,与间充质肿瘤细胞状态和肿瘤微环境免疫反应相关。
  • 潜伏免疫型胶质母细胞瘤患者在接受免疫检查点治疗后总生存期较短(P=0.0041)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Glioblastoma is a highly aggressive type of brain tumor for which there is no curative treatment available. Immunotherapies have shown limited responses in unselected patients, and there is an urgent need to identify mechanisms of treatment resistance to design novel therapy strategies. METHODS: Here we investigated the phenotypic and transcriptional dynamics at single-cell resolution during nivolumab immune checkpoint treatment of glioblastoma patients. RESULTS: We present the integrative paired single-cell RNA-seq analysis of 76 tumor samples from patients in a clinical trial of the PD-1 inhibitor nivolumab and untreated patients. We identify a distinct aggressive phenotypic signature in both tumor cells and the tumor microenvironment in response to nivolumab. Moreover, nivolumab-treatment was associated with an increased transition to mesenchymal stem-like tumor cells, and an increase in TAMs and exhausted and proliferative T cells. We verify and extend our findings in large external glioblastoma dataset (n = 298), develop a latent immune signature and find 18% of primary glioblastoma samples to be latent immune, associated with mesenchymal tumor cell state and TME immune response. Finally, we show that latent immune glioblastoma patients are associated with shorter overall survival following immune checkpoint treatment (P = .0041). CONCLUSIONS: We find a resistance mechanism signature in one fifth of glioblastoma patients associated with a tumor-cell transition to a more aggressive mesenchymal-like state, increase in TAMs and proliferative and exhausted T cells in response to immunotherapy. These patients may instead benefit from neuro-oncology therapies targeting mesenchymal tumor cells.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Hendriksen JD, Locallo A, Maarup S, et al. Immunotherapy drives mesenchymal tumor cell state shift and TME immune response in glioblastoma patients. Neuro Oncol. 2024. PMID: 38695342. doi:10.1093/neuonc/noae085

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。